Maravai LifeSciences

Maravai LifeSciences

Offers oligonucleotide synthesis and immunohistochemistry

Overview

Maravai LifeSciences provides tools and services for life sciences research and bioproduction, including supplying oligonucleotides for PCR, next-generation sequencing (NGS), and gene editing, as well as immunohistochemistry for cancer research, serving academic institutions, biotechnology firms, and pharmaceutical companies. Oligonucleotide synthesis creates short DNA or RNA strands used in PCR, sequencing, and genome editing workflows; immunohistochemistry uses labeled antibodies to detect proteins in tissue samples. It differentiates itself by combining investment and operational support to incubate and scale life science companies while offering essential research tools. Its goal is to catalyze the development of life science companies to advance human health by providing capital, expertise, and essential research tools.

About Maravai LifeSciences

Simplify's Rating
Why Maravai LifeSciences is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Venture Capital

Biotechnology

Healthcare

Company Size

51-200

Company Stage

IPO

Headquarters

San Diego, California

Founded

2014

Your Connections

People at Maravai LifeSciences who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 TriLink revenue grew 65%, showing strong non-pandemic demand.
  • Debt fell to $150 million and maturity extended to 2032, improving flexibility.
  • Officinae Bio adds AI-enabled mRNA design and DNA/RNA capabilities for nucleic-acid therapies.

What critics are saying

  • COVID-related TriLink orders still contributed $14.3 million in Q1 2026 revenue.
  • Securities-law investigations create distraction, legal expense, and possible shareholder litigation.
  • Acquisition integration failures can delay synergies and leave Maravai with duplicated costs.

What makes Maravai LifeSciences unique

  • Maravai supplies critical nucleic-acid, enzyme, and antibody products for vaccine development.
  • Its brands serve biopharma, diagnostics, and academic researchers from discovery through commercialization.
  • Glen Research and TriLink extend reach across oligonucleotide synthesis and mRNA workflows.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1.8B

Above

Industry Average

Funded Over

2 Rounds

Secondary funding comparison data is currently unavailable. We're working to provide this information soon!
Secondary Funding Comparison
Coming Soon

Benefits

Health Insurance

Company Equity

Fertility Treatment Support

Family Planning Benefits

401(k) Retirement Plan

Paid Vacation

Stock Price

Company News

Valley Times-News
Mar 6th, 2025
MRVI INVESTOR ALERT: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

MRVI INVESTOR ALERT: Maravai LifeSciences Holdings, Inc. investors with substantial losses have opportunity to lead Class Action lawsuit.

Tidewater News
Mar 1st, 2025
MRVI INVESTIGATION NOTICE: Investigation Launched into Maravai LifeSciences Holdings, Inc. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm

SAN DIEGO, March 1, 2025 /PRNewswire/ - The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.

Investing.com
Jan 28th, 2025
Maravai LifeSciences expands mRNA manufacturing with new acquisition

SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property and assets from Molecular Assemblies, Inc.

LifeCare News
Dec 5th, 2024
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

Maravai LifeSciences appoints R. Andrew Eckert as Chairman of the Board of Directors.

San Diego Business Journal
Nov 25th, 2024
Maravai to Acquire Officinae Bio

More recently, Maravai acquired the molecular biology enzyme provider Alphazyme, LLC, in 2022.

Recently Posted Jobs

Sign up to get curated job recommendations

Maravai LifeSciences is Hiring for 4 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →